GlassScriptPhysician profile
Marygrace Johnson
NPI 1174066799
$15,150.07
in general payments reported to CMS, 2019-2025
38 companies · $3,780 in 2025
The $3,780 reported for 2025 was more than what 98% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $2,128 · 2022: $2,558 · 2023: $3,162 · 2024: $3,522 · 2025: $3,780.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $10K · Education: $99.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $10,364.95 |
| Education | $99.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $3,570.04 | 2021-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $2,315.90 | 2021-2025 | Entyvio, Gattex, Eohilia |
| Janssen Biotech, INC. | $1,897.17 | 2021-2025 | Tremfya, Stelara, Simponi Aria |
| Aimmune Therapeutics, INC. | $923.56 | 2024-2025 | Zenpep, Vowst |
| Daiichi Sankyo INC. | $779.48 | 2021-2025 | Injectafer |
| Qol Medical, LLC | $642.18 | 2022-2025 | Sucraid, Sucraid |
| Nestle Healthcare Nutrition INC. | $623.00 | 2021-2023 | |
| Intercept Pharmaceuticals, INC. | $451.96 | 2021-2023 | Ocaliva |
| Madrigal Pharmaceuticals | $447.13 | 2024-2025 | Rezdiffra, Resmetirom |
| Regeneron Healthcare Solutions, INC. | $370.50 | 2022-2025 | Dupixent |
| Phathom Pharmaceuticals, INC. | $335.35 | 2024-2025 | Voquezna |
| Ipsen Biopharmaceuticals, INC | $308.49 | 2024-2025 | Iqirvo, Bylvay |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $267.97 | 2021-2025 | Xifaxan |
| Lilly USA, LLC | $252.28 | 2024-2025 | Omvoh |
| Ardelyx, INC. | $244.83 | 2023-2024 | Ibsrela |
Show all 38 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $203.27 | 2021-2023 | Avsola |
| Celgene Corporation | $199.31 | 2021-2024 | Zeposia |
| Gilead Sciences, INC. | $189.43 | 2021-2025 | |
| Pfizer INC. | $183.81 | 2021-2025 | |
| Vivus LLC | $177.64 | 2021-2023 | Qsymia |
| Merck Sharp & Dohme LLC | $154.14 | 2021-2024 | Dificid |
| Janssen Scientific Affairs, LLC | $93.50 | 2025 | Tremfya, Stelara |
| Organon LLC | $73.52 | 2022-2023 | Renflexis, Hadlima |
| Genzyme Corporation | $61.85 | 2021-2024 | |
| Pharmacosmos Therapeutics INC. | $59.99 | 2021-2025 | Monoferric |
| Evoke Pharma, INC. | $41.47 | 2021 | |
| Horizon Therapeutics Plc | $39.63 | 2021-2022 | |
| Novo Nordisk INC | $34.34 | 2025 | Wegovy |
| Alfasigma USA, INC. | $30.62 | 2022 | |
| Fresenius Kabi USA, LLC | $30.28 | 2024 | Smoflipid |
| Mallinckrodt Hospital Products INC. | $27.60 | 2024 | Terlivaz |
| Ferring Pharmaceuticals INC. | $25.02 | 2023 | Rebyota |
| Astrazeneca Pharmaceuticals LP | $21.58 | 2022 | |
| Argenx US, INC. | $16.65 | 2022 | |
| Ironwood Pharmaceuticals, INC | $15.09 | 2021 | |
| Acacia Pharma INC | $15.00 | 2021 | |
| Tersera Therapeutics LLC | $13.53 | 2025 | Quzyttir |
| Echosens North America, INC. | $12.96 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Marygrace Johnson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.